Bilateral atypical femoral fractures after long-term alendronate therapy: a case report.
Bisphosphonates therapy has been shown to decrease the risk of vertebral, non-vertebral, and hip fractures in postmenopausal women. However the long-term safety of bisphosphonates use has been questioned. Recent reports have demonstrated the association between long-term alendronate therapy with low-energy subtrochanteric fracture or diaphyseal femoral fractures in a small number of patients. The author reported the first case of bilateral atypical femoral fractures in postmenopausal women with osteoporosis receiving long-term alendronate therapy.
Bamrungsong
Tachchai
T
Department of Orthopedics, Phranakhon Si Ayutthaya Hospital, Phranakhon Si Ayutthaya, Thailand.
Pongchaiyakul
Chatlert
C
D000368:Aged; D019386:Alendronate / Q000009:adverse effects*; D044466:Asian People; D050071:Bone Density Conservation Agents / Q000009:adverse effects*; D005260:Female; D005264:Femoral Fractures / Q000139:chemically induced* / Q000000981:diagnostic imaging; D006801:Humans; D015663:Osteoporosis, Postmenopausal / Q000150:complications / Q000188:drug therapy*; D011859:Radiography; D013997:Time Factors
D050071:Bone Density Conservation Agents; D019386:Alendronate